Next Generation Transcriptomics-based Precision Oncology

About this Class

During this webinar, Computational Biologist Dr. Eytan Ruppin will present on “SELECT,” a computational approach that aims to identify clinically relevant synthetic lethal interactions, thereby harnessing them to predict patient response to cancer therapy from the bulk tumor transcriptome. Tested on a broad collection of targeted and immunotherapy clinical trials, SELECT is predictive of patients’ response in 80% of those and in the recent multi-arm WINTHER clinical trial. The session will also cover:

• “MadHitter” and “PERCEPTION,” two new computational approaches for guiding precision cancer therapy based on single cell tumor transcriptomics.
• future challenges that need to be addressed to further advance transcriptomics-based precision oncology, including the development of a new precision oncology expression-based approach starting from histopathological images.

The Data Science Seminar Series presents talks from innovators in the cancer research and informatics communities both within and outside of NCI. Presenter: Eytan Ruppin, M.D., Ph.D. Dr. Ruppin is the chief and senior investigator of NCI’s Cancer Data Science Laboratory. He’s a trained computational biologist whose research is focused on developing and harnessing data science approaches for the integration of multi-omics data to better understand the pathogenesis of cancer, its evolution, and treatment.